COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
20 hedge funds and large institutions have $434K invested in COSCIENS Biopharma Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 3 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
25% more funds holding
Funds holding: 16 → 20 (+4)
0.01% less ownership
Funds ownership: 0.03% → 0.02% (-0.01%)
22% less capital invested
Capital invested by funds: $555K → $434K (-$121K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$20.5K |
| 2 |
Two Sigma Advisers
New York
|
+$10.7K |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$10.5K |
| 4 |
RFA
Reilly Financial Advisors
La Mesa,
California
|
+$2.22K |
| 5 |
TC
Truvestments Capital
Sarasota,
Florida
|
+$814 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$221K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$28K |
| 3 |
Jane Street
New York
|
-$6K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$185 |
CSCI Hedge Fund Activity: Q4 2020 in Review
20 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q4 2020, worth a combined $434K — down 22% from $555K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CSCI positions and 3 closed out — a net gain of 4 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $20.5K. The largest seller was Morgan Stanley, cutting an estimated $221K.
- 20 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q4 2020, up from 16 in Q3 2020.
- Funds reported $434K of COSCIENS Biopharma Inc. Common Stock stock for Q4 2020, down 22% quarter-over-quarter.
- 7 funds opened new COSCIENS Biopharma Inc. Common Stock positions in Q4 2020 and 3 closed out, a net change of +4 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q4 2020 was UBS Group, an estimated $20.5K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q4 2020 was Morgan Stanley, an estimated $221K sold.
Based on aggregated 13F filings for Q4 2020.